Boston Scientific Corporation $BSX Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP grew its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 4.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,314,323 shares of the medical equipment provider’s stock after purchasing an additional 196,830 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.29% of Boston Scientific worth $421,200,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the stock. Insigneo Advisory Services LLC lifted its position in Boston Scientific by 13.3% in the third quarter. Insigneo Advisory Services LLC now owns 15,653 shares of the medical equipment provider’s stock valued at $1,528,000 after acquiring an additional 1,837 shares during the last quarter. Great Lakes Retirement Inc. increased its position in shares of Boston Scientific by 2.6% during the third quarter. Great Lakes Retirement Inc. now owns 23,585 shares of the medical equipment provider’s stock worth $2,303,000 after purchasing an additional 598 shares in the last quarter. Cresset Asset Management LLC lifted its holdings in shares of Boston Scientific by 30.7% in the 3rd quarter. Cresset Asset Management LLC now owns 22,184 shares of the medical equipment provider’s stock valued at $2,166,000 after purchasing an additional 5,212 shares during the last quarter. Picton Mahoney Asset Management boosted its position in shares of Boston Scientific by 2.3% in the 3rd quarter. Picton Mahoney Asset Management now owns 340,103 shares of the medical equipment provider’s stock valued at $33,205,000 after purchasing an additional 7,734 shares during the period. Finally, Level Four Advisory Services LLC grew its stake in Boston Scientific by 8.4% during the 3rd quarter. Level Four Advisory Services LLC now owns 10,030 shares of the medical equipment provider’s stock worth $979,000 after buying an additional 781 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: CE-mark approval expands Farapulse pulsed-field ablation labeling in Europe, opening reimbursement/market access for persistent atrial fibrillation treatments and supporting procedure growth in a high-value cardiology franchise. Boston Scientific gets Farapulse label expansion in Europe
• Positive Sentiment: TD Cowen reiterated a Buy and kept a $100 price target, arguing recent share weakness presents a buying opportunity given strong organic growth and margin expansion potential. Boston Scientific: Share Price Weakness Creates Opportunity
• Positive Sentiment: Bank of America reaffirmed a Buy on BSX, noting near-term resets but citing 2027 growth drivers that support upside — a signal that institutional analysts still favor the company’s medium-term thesis. Boston Scientific: Near-Term EP Reset but 2027 Growth Drivers Support Buy Rating
• Positive Sentiment: Unusual options activity: traders bought ~41,571 call contracts (≈+138% vs. typical), indicating short-term bullish/speculative positioning that can amplify upside if positive catalysts arrive.
• Neutral Sentiment: Q4 results showed an EPS beat and ~16% revenue growth year-over-year, with FY26 guidance set (Q1 EPS 0.780–0.800; FY EPS 3.430–3.490) — solid fundamentals but not enough to offset recent sentiment-driven selling.
• Neutral Sentiment: Management presented at the TD Cowen healthcare conference; the transcript provides detail on strategy and drivers but contains no immediate surprise to change the current market narrative. Conference Presentation Transcript
• Neutral Sentiment: Market commentary pieces suggest the pullback has created a buying opportunity for long-term investors, but they also highlight the stock’s recent volatility which may keep traders cautious. Is It Time To Reconsider Boston Scientific After The Recent Share Price Pullback
• Negative Sentiment: Pomerantz LLP announced an investigation into Boston Scientific on behalf of investors, which adds legal overhang and potential litigation risk that can pressure the stock. Pomerantz Law Firm Investigation
• Negative Sentiment: Portnoy Law Firm also opened an investigation into possible securities fraud, compounding legal uncertainty and contributing to downward pressure on the share price. Portnoy Law Firm Investigation

Boston Scientific Stock Down 2.3%

Shares of Boston Scientific stock opened at $72.13 on Thursday. Boston Scientific Corporation has a one year low of $71.83 and a one year high of $109.50. The company has a market cap of $107.03 billion, a P/E ratio of 37.18, a PEG ratio of 1.02 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The firm has a fifty day moving average of $85.98 and a two-hundred day moving average of $94.99.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business’s revenue was up 15.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on BSX. UBS Group reduced their price objective on Boston Scientific from $140.00 to $120.00 and set a “buy” rating for the company in a research note on Thursday, February 5th. Evercore reduced their price target on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Mizuho decreased their price target on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Finally, Oppenheimer reduced their target price on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a report on Friday, January 16th. Two research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and an average price target of $108.36.

Insider Activity at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.50% of the stock is owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.